Vericiguat for Vascular Function and Organ Injury in Heart Surgery
This study is looking at how a medication called vericiguat affects blood vessel function and markers of kidney and brain injury in people having heart surgery. You would receive either vericiguat or a placebo (an inactive substance) for two days before your surgery and on the day of surgery. Researchers want to see if vericiguat improves how your blood vessels work and reduces signs of damage to your kidneys and brain. The study aims to enroll 170 participants who are at least 18 years old and scheduled for elective open-heart surgery. The study's status is currently unclear.
- Study design
- This is an interventional study where participants are randomly assigned to receive either vericiguat or a placebo. It plans to enroll 170 participants.
- What's involved
- You would take either vericiguat or a placebo orally starting 2 days before your heart surgery through the day of surgery. Blood and urine samples will be collected from enrollment through postoperative day 2.
- Compensation
- Not stated in the trial record.
- Follow-up
- Markers of brain and kidney injury will be measured through postoperative day 2.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Marcos Lopez, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Brachial artery flow-mediated dilationDay of surgery
Percent change in brachial artery diameter from baseline to maximum post-forearm ischemia adjusted for shear-rate (Aim 1 primary outcome).
- Ex vivo vascular relaxationDay of surgery
Ex vivo arterial relaxation (percent) in participants with available vascular tissue (Aim 1 primary outcome)
- Ubiquitin C-terminal hydrolase L1 (UCHL1) plasma concentrationEnrollment through postoperative day 2
UCHL1 will be measured in plasma to quantify effects of vericiguat vs. placebo on neuronal injury (Aim 2 primary neuronal outcome)
- Neutrophil gelatinase associated lipocalin (NGAL) urine concentrationEnrollment through postoperative day 2
NGAL will be measured in urine to quantify effects of vericiguat vs. placebo on markers of renal injury (Aim 2 primary renal outcome)